Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Nefrología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Terminado
Fase 1
ClinicalTrials.gov
A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease
INTERVENTIONAL
Inicio: 1 de may de 2013
ID: NCT01839526
Completado
ClinicalTrials.gov
NordiNet® International Outcome Study-Observational Prospective Study on Patients Treated With Norditropin®
OBSERVATIONAL
Inicio: 1 de abr de 2006
ID: NCT00960128
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab Plus Standard of Care Versus Placebo Plus Standard of Care in Adult Subjects With Active Lupus Nephritis
INTERVENTIONAL
Inicio: 12 de jul de 2012
ID: NCT01639339
Terminado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)
INTERVENTIONAL
Inicio: 5 de abr de 2018
ID: NCT03608033
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
INTERVENTIONAL
Inicio: 27 de sept de 2016
ID: NCT02876835
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants With Chronic Kidney Disease and High Blood Pressure
INTERVENTIONAL
Inicio: 3 de mar de 2025
ID: NCT06742723
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Three-Arm, Randomized, Open-Label Study Of Interferon Alfa Alone, CCI-779 Alone, And The Combination Of Interferon Alfa And CCI-779 In First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.
INTERVENTIONAL
Inicio: 1 de jul de 2003
ID: NCT00065468
Completado
Fase 4
ClinicalTrials.gov
Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy
INTERVENTIONAL
Inicio: 1 de ene de 1996
ID: NCT00367562
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
INTERVENTIONAL
Inicio: 7 de jul de 2017
ID: NCT03138512
Reclutando
Fase 2
ClinicalTrials.gov
A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1920 in Adult Participants With PMN (Primary Membranous Nephropathy) Who Are at a High Risk for Disease Progression
INTERVENTIONAL
Inicio: 19 de sept de 2025
ID: NCT07157787
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study in Hemodialysis Participants With Anemia of Chronic Kidney Disease to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Recombinant Human Erythropoietin or Its Analogs
INTERVENTIONAL
Inicio: 5 de sept de 2018
ID: NCT03400033
Completado
ClinicalTrials.gov
Characteristics and Management of Acute Kidney Injury in Hospitalized Patients With Cirrhosis: a Multicenter Intercontinental Observational Prospective Study: The International Club of Ascites GLOBAL AKI Project
OBSERVATIONAL
Inicio: 1 de jul de 2022
ID: NCT05387811
Reclutando
Fase 2
ClinicalTrials.gov
Efficacy, Safety and Pharmacokinetics of NNC0519-0130 Once Weekly s.c. Versussemaglutide 1.0 mg and Placebo in People With Chronic Kidney Disease, With or Without Type 2 Diabetes, and With Overweight or Obesity: a Proof-of-concept and Dose-finding Study
INTERVENTIONAL
Inicio: 2 de dic de 2024
ID: NCT06717698
Reclutando
Fase 3
ClinicalTrials.gov
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)
INTERVENTIONAL
Inicio: 3 de dic de 2024
ID: NCT06685757
Terminado
Fase 2
ClinicalTrials.gov
A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
INTERVENTIONAL
Inicio: 1 de oct de 2020
ID: NCT04492722
Activo, no recluta
Fase 3
ClinicalTrials.gov
ZEUS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Established Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease and Systemic Inflammation
INTERVENTIONAL
Inicio: 30 de ago de 2021
ID: NCT05021835
Terminado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function
INTERVENTIONAL
Inicio: 19 de dic de 2017
ID: NCT03315143
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
INTERVENTIONAL
Inicio: 16 de oct de 2014
ID: NCT02231749
Completado
Fase 4
ClinicalTrials.gov
A Multicenter, Four Arm, Randomized, Open Label Clinical Study Investigating Optimized Dosing in a Prograf®-/Advagraf®-Based Immunosuppressive Regimen in Kidney Transplant Subjects (OSAKA Study)
INTERVENTIONAL
Inicio: 14 de may de 2008
ID: NCT00717470
Completado
Fase 3
ClinicalTrials.gov
A 12-month, Multicenter, Open Label, Randomized, Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced CNI, and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients With a 24-month Additional Safety Follow-up.
INTERVENTIONAL
Inicio: 17 de ago de 2012
ID: NCT01544491
Anterior
1
...
15
16
17
...
434
Siguiente
Filtros